{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:38:37Z","timestamp":1792809517674,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01044-8","type":"journal-article","created":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T14:08:49Z","timestamp":1792764529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Trough Prediction Error of Japanese Population Pharmacokinetic Models for Teicoplanin After Loading in Cancer Patients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6048-2502","authenticated-orcid":false,"given":"Toshihisa","family":"Nakashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Shiotsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Okinaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironobu","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,23]]},"reference":[{"key":"1044_CR1","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dkab499","volume":"77","author":"Y Hanai","year":"2022","unstructured":"Hanai Y, Takahashi Y, Niwa T, Mayumi T, Hamada Y, Kimura T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother. 2022;77:869\u201379. https:\/\/doi.org\/10.1093\/jac\/dkab499.","journal-title":"J Antimicrob Chemother"},{"key":"1044_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1691\/ph.2025.5609","volume":"80","author":"T Nakashima","year":"2025","unstructured":"Nakashima T, Kobayashi O, Okinaka K, Shiotsuka M, Nakamura K, Ito A, et al. Comparison of vancomycin and teicoplanin for febrile neutropenia following hematopoietic stem cell transplantation. Pharmazie. 2025;80:132\u20136. https:\/\/doi.org\/10.1691\/ph.2025.5609.","journal-title":"Pharmazie"},{"key":"1044_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","volume":"39","author":"AP Wilson","year":"2000","unstructured":"Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin Pharmacokinet. 2000;39:167\u201383. https:\/\/doi.org\/10.2165\/00003088-200039030-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1044_CR4","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1093\/jac\/dkg147","volume":"51","author":"F Pea","year":"2003","unstructured":"Pea F, Brollo L, Viale P, Pavan F, Furlanut M. Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose. J Antimicrob Chemother. 2003;51:971\u20135. https:\/\/doi.org\/10.1093\/jac\/dkg147.","journal-title":"J Antimicrob Chemother"},{"key":"1044_CR5","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.jiac.2015.02.002","volume":"21","author":"A Nakamura","year":"2015","unstructured":"Nakamura A, Takasu O, Sakai Y, Sakamoto T, Yamashita N, Mori S, et al. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections. J Infect Chemother. 2015;21:449\u201355. https:\/\/doi.org\/10.1016\/j.jiac.2015.02.002.","journal-title":"J Infect Chemother"},{"key":"1044_CR6","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jiac.2016.01.019","volume":"22","author":"H Kato","year":"2016","unstructured":"Kato H, Hamada Y, Hagihara M, Hirai J, Nishiyama N, Koizumi Y, et al. Retrospective study of teicoplanin loading regimen that rapidly achieves target 15\u201330 mug\/mL serum trough concentration. J Infect Chemother. 2016;22:308\u201313. https:\/\/doi.org\/10.1016\/j.jiac.2016.01.019.","journal-title":"J Infect Chemother"},{"key":"1044_CR7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40360-020-00424-3","volume":"21","author":"T Ueda","year":"2020","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichiki K, Ishikawa K, Takai Y, et al. Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 \u03bcg\/mL using a regimen of 12 mg\/kg for five doses within the initial 3 days. BMC Pharmacol Toxicol. 2020;21:50. https:\/\/doi.org\/10.1186\/s40360-020-00424-3.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1044_CR8","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2010","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;52:e56-93. https:\/\/doi.org\/10.1093\/cid\/cir073.","journal-title":"Clin Infect Dis"},{"key":"1044_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/QCO.0b013e32835915c2","volume":"25","author":"IJ Abbott","year":"2012","unstructured":"Abbott IJ, Roberts JA. Infusional \u03b2-lactam antibiotics in febrile neutropenia: has the time come? Curr Opin Infect Dis. 2012;25:619\u201325. https:\/\/doi.org\/10.1097\/QCO.0b013e32835915c2.","journal-title":"Curr Opin Infect Dis"},{"key":"1044_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s40262-013-0086-1","volume":"52","author":"T Goulenok","year":"2013","unstructured":"Goulenok T, Fantin B. Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations. Clin Pharmacokinet. 2013;52:869\u201383. https:\/\/doi.org\/10.1007\/s40262-013-0086-1.","journal-title":"Clin Pharmacokinet"},{"key":"1044_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1097\/ftd.0000000000000270","volume":"38","author":"K Hirai","year":"2016","unstructured":"Hirai K, Ihara S, Kinae A, Ikegaya K, Suzuki M, Hirano K, et al. Augmented renal clearance in pediatric patients with febrile neutropenia associated with vancomycin clearance. Ther Drug Monit. 2016;38:393\u20137. https:\/\/doi.org\/10.1097\/ftd.0000000000000270.","journal-title":"Ther Drug Monit"},{"key":"1044_CR12","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/ftd.0000000000000906","volume":"43","author":"KI Sako","year":"2021","unstructured":"Sako KI, Nakamaru Y, Ikawa K, Maeda T, Goto S, Ishihara Y, et al. Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies. Ther Drug Monit. 2021;43:519\u201326. https:\/\/doi.org\/10.1097\/ftd.0000000000000906.","journal-title":"Ther Drug Monit"},{"key":"1044_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1691\/ph.2017.6811","volume":"72","author":"S Yoshida","year":"2017","unstructured":"Yoshida S, Suzuki A, Ohmori T, Niwa T, Okada H, Suzuki K, et al. A simplified chart for determining the initial loading dose of teicoplanin in critically ill patients. Pharmazie. 2017;72:53\u20137. https:\/\/doi.org\/10.1691\/ph.2017.6811.","journal-title":"Pharmazie"},{"key":"1044_CR14","first-page":"1","volume":"54","author":"K Nakayama","year":"2006","unstructured":"Nakayama K, Gemma H, Kaibara A, Niwa T. Population pharmacokinetics of teicoplanin in adult patients. Jpn J Chemother. 2006;54:1\u20136.","journal-title":"Jpn J Chemother."},{"key":"1044_CR15","first-page":"587","volume":"39","author":"K Oda","year":"2013","unstructured":"Oda K, Kasada T, Yamashita T, Nishida O, Takeshita Y. Estimating teicoplanin loading dose by revising its volume of distribution in the population pharmacokinetic parameter. Iryo Yakugaku (Jn J Pharm Health Care Sci). 2013;39:587\u201398.","journal-title":"Iryo Yakugaku (Jn J Pharm Health Care Sci)"},{"key":"1044_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59040758","author":"M Takigawa","year":"2023","unstructured":"Takigawa M, Tanaka H, Suwa J, Obara T, Maeda Y, Sato M, et al. Accuracy of therapeutic drug monitoring of teicoplanin at the onset of febrile neutropenia. Medicina (Kaunas). 2023. https:\/\/doi.org\/10.3390\/medicina59040758.","journal-title":"Medicina (Kaunas)"},{"key":"1044_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","volume":"20","author":"T Ueda","year":"2014","unstructured":"Ueda T, Takesue Y, Nakajima K, Ichki K, Wada Y, Komatsu M, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014;20:43\u20137. https:\/\/doi.org\/10.1016\/j.jiac.2013.08.006.","journal-title":"J Infect Chemother"},{"issue":"Suppl 1","key":"1044_CR18","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1086\/383054","volume":"39","author":"T Masaoka","year":"2004","unstructured":"Masaoka T. Evidence-based recommendations for antimicrobial use in febrile neutropenia in Japan: executive summary. Clin Infect Dis. 2004;39(Suppl 1):S49-52. https:\/\/doi.org\/10.1086\/383054.","journal-title":"Clin Infect Dis"},{"key":"1044_CR19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000180580","volume":"16","author":"DW Cockcroft","year":"1976","unstructured":"Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31\u201341. https:\/\/doi.org\/10.1159\/000180580.","journal-title":"Nephron"},{"key":"1044_CR20","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2165\/00003088-199426040-00005","volume":"26","author":"DJ Morgan","year":"1994","unstructured":"Morgan DJ, Bray KM. Lean body mass as a predictor of drug dosage. implications for drug therapy. Clin Pharmacokinet. 1994;26:292\u2013307. https:\/\/doi.org\/10.2165\/00003088-199426040-00005.","journal-title":"Clin Pharmacokinet."},{"key":"1044_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ijantimicag.2015.01.015","volume":"45","author":"AJ Brink","year":"2015","unstructured":"Brink AJ, Richards GA, Lautenbach EE, Rapeport N, Schillack V, van Niekerk L, et al. Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis. Int J Antimicrob Agents. 2015;45:647\u201351. https:\/\/doi.org\/10.1016\/j.ijantimicag.2015.01.015.","journal-title":"Int J Antimicrob Agents"},{"key":"1044_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2025.102871","volume":"31","author":"Y Shimizu","year":"2025","unstructured":"Shimizu Y, Hanada K, Watanabe T, Araki M, Aoyama K, Sakai T, et al. Impact of hypoalbuminemia severity on total teicoplanin concentrations after 3 days loading dose: a retrospective observational study. J Infect Chemother. 2025;31:102871. https:\/\/doi.org\/10.1016\/j.jiac.2025.102871.","journal-title":"J Infect Chemother"},{"key":"1044_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003088-200443060-00004","volume":"43","author":"F Pea","year":"2004","unstructured":"Pea F, Viale P, Candoni A, Pavan F, Pagani L, Damiani D, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43:405\u201315. https:\/\/doi.org\/10.2165\/00003088-200443060-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1044_CR24","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/ftd.0000000000001320","volume":"47","author":"N Kondo","year":"2025","unstructured":"Kondo N, Tanaka R, Tatsuta R, Tsushita H, Hashimoto T, Hiramatsu K, et al. Effect of augmented renal clearance and febrile neutropenia on initial trough level and clearance of teicoplanin. Ther Drug Monit. 2025;47:385\u201392. https:\/\/doi.org\/10.1097\/ftd.0000000000001320.","journal-title":"Ther Drug Monit"},{"key":"1044_CR25","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jiac.2016.01.024","volume":"22","author":"A Kozono","year":"2016","unstructured":"Kozono A, Hiraki Y, Adachi R, Nagano M, Inoue D, Tsuji Y, et al. Comparison of predictive accuracy of teicoplanin concentration using creatinine clearance and glomerular filtration rate estimated by serum creatinine or cystatin C. J Infect Chemother. 2016;22:314\u20138. https:\/\/doi.org\/10.1016\/j.jiac.2016.01.024.","journal-title":"J Infect Chemother"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01044-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01044-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:04:36Z","timestamp":1792807476000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01044-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":25,"alternative-id":["1044"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01044-8","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"assertion":[{"value":"22 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to disclose regarding this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Institutional Review Board of the National Cancer Center (approval no. 2019-058) and was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective observational study was conducted using an opt-out procedure; patients were informed of the study and given the opportunity to decline participation (e.g., via the institutional website), in accordance with the approval of the Institutional Review Board of the National Cancer Center. Therefore, written informed consent was not obtained.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}